Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose

Eur Urol. 1999 Dec;36(6):582-7. doi: 10.1159/000020052.


Objectives: The aim of this study was to evaluate whether pelvic lymph node metastases in patients with neoplasms of the bladder or prostate can be detected applying positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose (FDG-PET).

Methods: Eight patients with bladder cancer and 17 patients with prostate cancer were examined with FDG-PET before pelvic lymph node dissection. Results of PET were then compared to histology of pelvic lymph nodes obtained at surgery.

Results: Lymph node metastases were detected by histopathological examination in 3 patients with bladder cancer and in 6 patients with prostate cancer. At the sites with histologically proven metastases, increased FDG uptake suspicious of metastatic disease was found in 2/3 and 4/6 patients, respectively. The smallest detected metastasis was a micrometastasis with a diameter of 0.9 cm. In 3 additional patients who all had histopathologically proven micrometastases ( </=0.5 cm), FDG uptake was within the normal range. No false-positive results were obtained.

Conclusions: These results suggest that FDG-PET may be a valuable diagnostic tool in the staging of pelvic lymph nodes in bladder and prostate cancer.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Deoxyglucose
  • Female
  • Fluorine Radioisotopes*
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis / diagnostic imaging*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pelvis / diagnostic imaging*
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery
  • Sensitivity and Specificity
  • Tomography, Emission-Computed*
  • Urinary Bladder Neoplasms / pathology*
  • Urinary Bladder Neoplasms / surgery


  • Fluorine Radioisotopes
  • Deoxyglucose